Cumberland to present clinical trial data of Caldolor at the AAPM annual meeting

NewsGuard 100/100 Score

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that data from two key clinical trials for Caldolor®, an intravenous formulation of ibuprofen approved for treatment of pain and fever in adults, will be presented at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting to be held in Phoenix, Ariz., on October 8-11, 2009.

Data from the following clinical trials of Caldolor will be displayed in poster presentations on Saturday, October 10, 2009, from 1:30-3:00 pm Mountain Time:

  • A phase III dose ranging pain study entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults" will be presented by principal author, Stephen R. Southworth, MD, FACS (study 008A, poster #49).
  • A phase III abdominal hysterectomy pain study entitled "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Ibuprofen for the Management of Postoperative Pain in Adults," authored by Peter Kroll, M.D., will be presented by co-author Laura Meadows, BC, CRCC (study 008B, poster #50).

In conjunction with the presentations, copies of the posters will be available on Cumberland's website at http://investor.shareholder.com/cpix/events.cfm, or by contacting the Company at 615-255-0068.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions